Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Human antigen R and drug resistance in tumors.

Zhou F, Zhang F, Zhou C, Liang M, Cai Z, Lv H, Li W, Wei X.

Invest New Drugs. 2019 Jan 5. doi: 10.1007/s10637-018-00723-x. [Epub ahead of print] Review.

PMID:
30612309
2.

Multiple functions of HuR in urinary tumors.

Zhang F, Cai Z, Lv H, Li W, Liang M, Wei X, Zhou F.

J Cancer Res Clin Oncol. 2019 Jan;145(1):11-18. doi: 10.1007/s00432-018-2778-2. Epub 2018 Oct 28. Review.

PMID:
30370480
3.

RNA Binding Proteins in Intestinal Epithelial Biology and Colorectal Cancer.

Chatterji P, Rustgi AK.

Trends Mol Med. 2018 May;24(5):490-506. doi: 10.1016/j.molmed.2018.03.008. Epub 2018 Apr 5. Review.

PMID:
29627433
4.

Complex HuR function in pancreatic cancer cells.

Brody JR, Dixon DA.

Wiley Interdiscip Rev RNA. 2018 May;9(3):e1469. doi: 10.1002/wrna.1469. Epub 2018 Feb 16. Review.

5.

Long noncoding RNAs coordinate functions between mitochondria and the nucleus.

Dong Y, Yoshitomi T, Hu JF, Cui J.

Epigenetics Chromatin. 2017 Aug 23;10(1):41. doi: 10.1186/s13072-017-0149-x. Review.

6.

Current Evidence and Future Perspectives on HuR and Breast Cancer Development, Prognosis, and Treatment.

Kotta-Loizou I, Vasilopoulos SN, Coutts RH, Theocharis S.

Neoplasia. 2016 Nov;18(11):674-688. doi: 10.1016/j.neo.2016.09.002. Epub 2016 Oct 18. Review.

7.

Dysregulation of TTP and HuR plays an important role in cancers.

Wang H, Ding N, Guo J, Xia J, Ruan Y.

Tumour Biol. 2016 Nov;37(11):14451-14461. Epub 2016 Sep 19. Review.

PMID:
27644249
8.

Cytoskeleton-Dependent Transport as a Potential Target for Interfering with Post-transcriptional HuR mRNA Regulons.

Eberhardt W, Badawi A, Biyanee A, Pfeilschifter J.

Front Pharmacol. 2016 Aug 17;7:251. doi: 10.3389/fphar.2016.00251. eCollection 2016. Review.

9.

Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer.

Mert U, Sanlioglu AD.

Cell Mol Life Sci. 2017 Jan;74(2):245-255. doi: 10.1007/s00018-016-2321-z. Epub 2016 Aug 10. Review.

PMID:
27510421
10.

Posttranslational control of HuR function.

Grammatikakis I, Abdelmohsen K, Gorospe M.

Wiley Interdiscip Rev RNA. 2017 Jan;8(1). doi: 10.1002/wrna.1372. Epub 2016 Jun 16. Review.

11.

The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms.

Chand S, O'Hayer K, Blanco FF, Winter JM, Brody JR.

Int J Biol Sci. 2016 Jan 27;12(3):273-82. doi: 10.7150/ijbs.14951. eCollection 2016. Review.

12.

Posttranscriptional regulation of FOXO expression: microRNAs and beyond.

Urbánek P, Klotz LO.

Br J Pharmacol. 2017 Jun;174(12):1514-1532. doi: 10.1111/bph.13471. Epub 2016 May 2. Review.

13.

Progress on the relationship between miR-125 family and tumorigenesis.

Yin H, Sun Y, Wang X, Park J, Zhang Y, Li M, Yin J, Liu Q, Wei M.

Exp Cell Res. 2015 Dec 10;339(2):252-60. doi: 10.1016/j.yexcr.2015.09.015. Epub 2015 Sep 25. Review.

PMID:
26407906
14.

Multifaceted roles of HSF1 in cancer.

Jiang S, Tu K, Fu Q, Schmitt DC, Zhou L, Lu N, Zhao Y.

Tumour Biol. 2015 Jul;36(7):4923-31. doi: 10.1007/s13277-015-3674-x. Epub 2015 Jun 25. Review.

PMID:
26108999
15.

NEDDylation in liver cancer: The regulation of the RNA binding protein Hu antigen R.

Fernández-Ramos D, Martínez-Chantar ML.

Pancreatology. 2015 Jul;15(4 Suppl):S49-54. doi: 10.1016/j.pan.2015.03.006. Epub 2015 Mar 20. Review.

PMID:
25841271
16.

RNA-stabilizing proteins as molecular targets in cardiovascular pathologies.

Suresh Babu S, Joladarashi D, Jeyabal P, Thandavarayan RA, Krishnamurthy P.

Trends Cardiovasc Med. 2015 Nov;25(8):676-83. doi: 10.1016/j.tcm.2015.02.006. Epub 2015 Feb 20. Review.

17.

Targeting the multifaceted HuR protein, benefits and caveats.

Zucal C, D'Agostino V, Loffredo R, Mantelli B, NatthakanThongon, Lal P, Latorre E, Provenzani A.

Curr Drug Targets. 2015;16(5):499-515. Review.

PMID:
25706256
18.

The role of the small GTPase Rab31 in cancer.

Chua CE, Tang BL.

J Cell Mol Med. 2015 Jan;19(1):1-10. doi: 10.1111/jcmm.12403. Epub 2014 Dec 3. Review.

19.

HuR: a promising therapeutic target for angiogenesis.

Dong R, Yang GD, Luo NA, Qu YQ.

Gland Surg. 2014 Aug;3(3):203-6. doi: 10.3978/j.issn.2227-684X.2014.03.02. Review.

20.

Clinical significance of HuR expression in human malignancy.

Kotta-Loizou I, Giaginis C, Theocharis S.

Med Oncol. 2014 Sep;31(9):161. doi: 10.1007/s12032-014-0161-y. Epub 2014 Aug 13. Review.

PMID:
25112469

Supplemental Content

Loading ...
Support Center